source
- Bristol Myers Squibb partners with Hengrui Pharma in $15.2 billion, 13-asset dealBristol Myers Squibb announced a partnership with China’s Hengrui Pharma that includes 13 assets. The transaction is reported to be valued at up to $15.2 billion, highlighting the scale of collabo…
- Bristol Myers Squibb signs up to $15.2 billion partnership with China's Hengrui PharmaBristol Myers Squibb announced a licensing partnership with China's Hengrui Pharma covering more than a dozen early-stage drug programs. The agreement includes a $600 million upfront payment to He…